Contrast Echocardiography in Clinical Practice

Abstract

After FDA approval of the new-generation contrast agent Optison (Mallinckrodt Medical, St. Louis, MO) January 1998, the use of contrast in echocardiograhy has become an invaluable tool. A review of 100 patients revealed contrast to be useful for endocardial border definition and wall segment analysis, enhancement of pulsed Doppler, and chamber opacification for the detection of thrombi. Evaluation of wall segments by two observers before and after injection of the contrast agent revealed an increase in the number of wall segments visualized by 4.8. Postinjection readings were consistent between the two observers. Routine contrast echocardiography may provide a more diagnostic study.